Apr 10, 2017 at 13:33 | Source: Moneycontrol.com
Dutasteride Soft Gelatin Capsules is therapeutically equivalent to the reference listed drug, Avodart capsules, 0.5 mg of GlaxoSmithCline.
Mar 07, 2017 at 21:56 | Source: PTI
Dilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
Mar 02, 2017 at 13:24 | Source: Moneycontrol.com
The index provider FTSE Russell will also add UPL, LIC Housing Finance and Piramal Enterprises to its large cap index. These changes will be effective from March 20, 2017.
Feb 23, 2017 at 17:54 | Source: Moneycontrol.com
Axis Direct recommended hold rating on Glaxosmithkline Consumer with a target price of Rs 5300 in its research report dated February 21, 2017.
Feb 20, 2017 at 13:25 | Source: Moneycontrol.com
Centrum is bearish on GlaxoSmithKline Pharma has recommended sell rating on the stock with a target price of Rs 1340 in its research report dated February 13, 2017.
Feb 20, 2017 at 08:26 | Source: CNBC-TV18
Idea Cellular | Axis Bank | Kotak Mahindra Bank | Hindustan Unilever | McNally Bharat | Havells | BPCL | GPT Infra | Mangalam Drugs and GSK Pharma are stocks, which are in the news today.
Feb 17, 2017 at 09:32 | Source: CNBC-TV18
Mahesh Nandurkar of CLSA expects FY18 Nifty earnings growth of 17 percent with small downside risk due to margin concern.
Feb 16, 2017 at 17:28 | Source: Moneycontrol.com
ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 6102 in its research report dated February 14, 2017.
Feb 16, 2017 at 11:28 | Source: Moneycontrol.com
Edelweiss recommended hold rating on Glaxosmithkline with a target price of Rs 5773 in its research report dated February 13, 2017.
Feb 14, 2017 at 10:00 | Source: CNBC-TV18
CLSA has downgraded HPCL to sell from outperform, with increased target price at Rs 540 from Rs 480 and EPS for FY17 by 8 percent & by 1-2 percent for FY18-19. Core refining margin was disappointing for third straight quarter, the brokerage house says, adding it relaxed EV/EBITDA multiple to 7.5x from 7x earlier.